首页 文献索引 SCI期刊 AI助手
首页 正文

Hepatology international. 2014 Oct;8(4):560-6. doi: 10.1007/s12072-014-9574-0 Q16.12025

Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C

索夫布韦联合利巴韦林治疗丙型肝炎的有利之处优于博赛普韦派流干扰素α及利巴韦林疗法 翻译改进

Shivakumar Narayanan  1, Kerry Townsend  2, Thomas Macharia  1, Adrian Majid  1, Amy Nelson  2, Robert R Redfield  1, Shyam Kottilil  3, Rohit Talwani  1, Anu Osinusi  1  2

作者单位 +展开

作者单位

  • 1 Division of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • 2 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10/11N204, 9000 Rockville Pike, Bethesda, MD, 20892, USA.
  • 3 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10/11N204, 9000 Rockville Pike, Bethesda, MD, 20892, USA. skottilil@niaid.nih.gov.

    • DOI: 10.1007/s12072-014-9574-0 PMID: 26202761

    摘要 Ai翻译

    Background: Triple therapy for the treatment of hepatitis C virus (HCV) with first-generation directly acting antiviral agents, the non-structural serine protease inhibitors boceprevir (BOC) and telaprevir have resulted in improved sustained virologic response (SVR) rates. However, a high incidence of adverse events (AEs), high pill burdens and drug interactions remain significant barriers to successful completion of therapy.... ...点击完成人机验证后继续浏览
    Copyright © Hepatology international. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Hepatology international

    缩写：HEPATOL INT

    ISSN：1936-0533

    e-ISSN：1936-0541

    IF/分区：6.1/Q1

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C